Meeting
2018 ASCO Annual Meeting
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.
Authors
Thomas J. George Jr.
NSABP Foundation and The University of Florida Health Cancer Center, Gainesville, FL
Thomas J. George Jr., Greg Yothers , James J. Lee , Samuel A. Jacobs , Melvin Deutsch , Carmen Joseph Allegra , Norman Wolmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT03102047
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3624)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3624
Abstract #
TPS3624
Poster Bd #
112b
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
First Author: Thomas J. George
Poster
2019 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
First Author: Thomas J. George
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
First Author: Thomas J. George
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon